The Year 2003 in Review: Microarray Industry Cashes in While Reaching a Inflection Point | GenomeWeb

When Affymetrix reports its fourth-quarter financial results a few weeks from now, the whole microarray industry should give itself a round of applause for a record year, financially speaking.

Affymetrix, the industry leader, is expected to report around $280 million in revenues for the year to round out an estimated $800 million in revenues for the industry in 2003, the biggest year yet for a technology not yet 10 years on the commercial market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.